Want to join the conversation?
$ABT's R&D expenses increased by 23.7% in 3Q15, due primarily to higher spending across its various businesses and the impact of higher restructuring costs recorded in the quarter. SG&A expenses for 3Q15 increased 4.5%, due primarily to the impact of the acquisition of CFR Pharmaceuticals in 3Q14 and Veropharm in 4Q14.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?